Benitec Biopharma reported a revenue-less QQ4 2024 quarter (calendar year 2024, quarter ended 2024-06-30) with a net loss of $4.72 million and an EBITDA of $-5.52 million. Gross profit stood at negative $0.091 million as there was effectively no product revenue; R&D expenses were $3.512 million and G&A/S&M combined were roughly $2.036 million, driving an operating loss of $5.548 million. Despite the operating burn, the company maintains a strong liquidity position, ending the period with approximately $50.93 million in cash and equivalents after a financing-driven inflow of roughly $40.07 million and a large common stock issuance of about $43.0 million. Net debt remains a substantial net-cash position (~$50.58 million), underscoring balance-sheet flexibility to fund pipeline advancement.
The quarterly results reflect Benitec’s development-stage status and heavy investment in its genetic medicine platform, including BB301 (AAV-based gene therapy for oculopharyngeal muscular dystrophy) and BB103 (HBV therapy). No revenue was recognized in QQ4 2024, which is typical for a biotech at this stage without approved products. The cash runway supports continued preclinical and early-stage clinical work, but the company faces ongoing dilution risk and dependence on timely pipeline progress or additional funding to reach meaningful milestones. Investors should monitor execution on BB301/BB103 timelines, potential partnering discussions, and any new financing activity that may impact share count and valuation.